CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations

• Published in: Annals of hematology 2019-07, Vol.98 (7), p.1641-1646
• Main Authors: Su, Long, Gao, SuJun, Tan, YeHui, Lin, Hai, Liu, XiaoLiang, Liu, ShanShan, Yang, Yan, Sun, JingNan, Li, Wei
• Format: Article
• Language: English
• Subjects: Hematology; Medical prognosis; Medicine; Medicine & Public Health; Mutation; Oncology; Original Article
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-019-03699-7

The aim of this study was to explore the clinical features and prognostic significance of CSF3R mutations in AML patients with CEBPA double mutations ( CEBPA dm ). One hundred one AML patients with CEBPA dm were retrospectively analyzed in this study. Mutation status of CSF3R gene, clinical features, and long-term outcomes were analyzed. The frequency of CSF3R mutations in patients with CEBPA dm was 19.80% (20/101). Patients with CSF3R mutations were associated with a lower platelet ( u  = 2.728, P  = 0.006) and higher leukocytes ( u  = 3.178, P  = 0.001) compared with those with wide-type CSF3R gene. The 5-year relapse-free survival (RFS) was 18.7% in patients with CSF3R mutations, which was significantly lower than those with wide-type CSF3R (31.8%) ( P  = 0.015). The 5-year overall survival (OS) was also significantly different between patients with and without CSF3R mutations (17.5% versus 57.4%, P  = 0.019). The prevalence of CSF3R mutations was high in AML patients with CEBPA dm , which indicated a poor prognosis, and CSF3R mutations may be a new potential candidate for prognostically re-stratifying AML patients with CEBPA dm .